聚焦伯恩斯坦_中国医药与生物技术:ASCO 2026第三部分 - 摘要(当基本面再次重要时)。Innovent (O): IBI363 plays in the less crowded segment of I/O-treated patients and shows a striking survival tail: 24-month OS of 48% in squamous and 43% in adenocarcinoma, versus 8% and 21.7% for docetaxel, and 29% for Dato-DXd in adeno.
聚焦伯恩斯坦_中国医药与生物技术:ASCO 2026第三部分 - 摘要(当基本面再次重要时)。Innovent (O): IBI363 plays in the less crowded segment of I/O-treated patients and shows a striking survival tail: 24-month OS of 48% in squamous and 43% in adenocarcinoma, versus 8% and 21.7% for docetaxel, and 29% for Dato-DXd in adeno.
聚焦伯恩斯坦_中国医药与生物技术:ASCO 2026第三部分 - 摘要(当基本面再次重要时)。Innovent (O): IBI363 plays in the less crowded segment of I/O-treated patients and shows a striking survival tail: 24-month OS of 48% in squamous and 43% in adenocarcinoma, versus 8% and 21.7% for docetaxel, and 29% for Dato-DXd in adeno.
覆盖 2026 年,全文共 25 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
适合行业研究员、战略规划等读者参考。
重点分析了医药、伯恩斯坦_中国医药与生物技术、ASCO、2026第三部分等议题。